KRAS and non-small cell lung carcinoma: In one of the largest real-world KRAS G12C analyses ever conducted (N = 743), the overall survival for the NSCLC G12C sub-cohort (15.2 vs. 14.8 months) was similar compared to a cohort that included all NSCLC patients (N = 7069), regardless of driver mutation status and irrespective of the type of therapy used [37].